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Abstract: The World Health Organization strongly recommends artemisinin-based combination 
therapy (ACT) regimens for the treatment of uncomplicated Plasmodium falciparum malaria 
cases in endemic areas. Among the combinations of compounds that are available at present, 
excellent results have been obtained for the artemisinin derivative artemether, in a combination 
galenic preparation with lumefantrine (artemether–lumefantrine, AL). Here, the pharmaco-
logical properties and the therapeutic options of both substances are briefly reviewed and a 
cursory overview is given on recent trials that have compared the therapeutic effects of AL in 
the standard 6-dose regimen with other antimalarials and combinations. In order to ensure the 
most achievable and reliable adherence and compliance of children in the treatment of malaria, 
a dispersible formulation of AL is now attainable. Recent reports on the emergence of resistance 
to ACT regimens in Asia, however, are alarming.
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Introduction
According to the 2008 World Malaria Report of the World Health Organization,1 an 
estimated 247 million confirmed clinical episodes of malaria were documented in 2006 
world-wide. However, and with respect to partly ineffective notification structures and 
the likelihood of underreporting cases in several malaria-endemic countries, the 5th to 
95th percentile uncertainty interval is wide and ranges from 189 million to 327 million 
cases. More than 880,000 fatalities due to Plasmodium falciparum malaria occurred 
in 2006, 91% of these in subSaharan Africa (SSA) and 85% occurring among children 
under 5 years of age.1 Indeed, every 36 seconds a patient dies from malaria. The 
promotion of artemisinin-based combination therapy (ACT) regimens in recent years 
as, in terms of effectiveness and the low probability of rapidly evolving resistance 
to such combinations, a first-line strategy to treat uncomplicated falciparum malaria 
has under the pronounced advocacy of WHO officially been adopted in all but three 
countries (Cape Verde, Dominican Republic, French Guyana) and the territory of 
Swaziland by June 2008. This does, however, not necessarily imply strict routine use of 
ACT in countries which have officially adopted the WHO suggestion, and compounds 
to which resistance has emerged (eg, chloroquine, sulfadoxine–pyrimethamine) are 
still widely used.
The active components and the galenic formulations of ACT combinations vary. 
At present, the formulations artemether–lumefantrine (AL), artesunate–amodiaquine, 
artesunate–mefloquine and artesunate–sulfadoxine–pyrimethamine are available and Therapeutics and Clinical Risk Management 2009:5 806
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recommended for treatment of malaria. Any preferential 
choice of one of these combinations in a region of intended 
implementation must critically depend both on the proven 
efficacy and the degree of parasite resistance to one of the 
components, either presently established or anticipated to 
manifest and spread in the foreseeable future. One of the 
most important issues of a memorandum of understanding 
that was endorsed and signed by the manufacturer Novartis 
and WHO in 2001 implies that AL (Coartem®) should be 
available at cost price in malaria-endemic areas.
Artemisinin
Artemisia annua (q ngh o [ ], syn. sweet wormwood, 
sweet Annie, sweet sagewort, annual wormwood) is a medici-
nal herb native to temperate areas of Asia, but naturalized 
throughout the world. A. annua grows with a single stem 
about 2 m tall, has alternating branches with fern-like leaves, 
yellow flowers, and a dulcet fragrance of camphor. In central 
China, especially in the province Hubei, the stems of A. annua 
are still today used as food in a salad-like form. The product 
is a slightly bitter salad with strong acid overtones from 
the spiced rice vinegar used as marinade. It is considered a 
delicacy and is more expensive to buy than meat.
Extracts of A. annua have been in use medically, in 
particular in the treatment of feverish conditions, but also 
of hemorrhoids, by Chinese herbalists for centuries. The 
extracts and their potency are referred to in both the Recipes 
for 52 Kinds of Diseases which were unearthed from the 
Mawangdui Han Dynasty tomb in Changsha 168 B.C.,2 
and in the Zhou Hou Bei Ji Fang ( ; Handbook 
of Prescriptions for Emergency Treatments), written in 
340 A.D. by Ge Hong of the Eastern Jin Dynasty. In 1596, 
artemisinin was mentioned by Li Shizhen as being effective 
in the treatment of malaria, although appropriate diagnostic 
tools for malaria were unvailable at that time.
The major active ingredient of A. annua, a sesquiterpene 
lactone (qinghaosu, artemisinin), was first isolated and 
chemically analyzed in detail in l972 by Chinese researchers 
and its antimalarial activity was proven in both mice and 
primates. The active ingredient is found in the glandular 
trichomes of the plant leaves, stems and inflorescences, 
and congregates in the upper portions of the plants at new 
growth. It can be extracted with low boiling point solvents, 
eg, diethylether. Subsequently, in l984 scientists at the Walter 
Reed Army Institute of Research crystallized the active 
component of A. annua. Artemesinin and its derivatives 
artemether, artesunate, arteether and others have since 
successfully been used to clear plasmodia, the causative 
infectious agents of malaria, from the blood more swiftly 
than do other drugs: artemisinin is indeed the fastest acting 
antimalarial available today. In particular, artesunate and 
artemether are known to clear parasitemias more rapidly 
than chloroquine, atovaquone–proguanil, mefloquine, quinine 
and sulfadoxine–pyrimethamine. Succesful and accelerated 
clearance applies, most importantly, also to otherwise resistant 
plasmodial strains. By inhibiting the maturation of plasmodial 
trophozoites, artemisinins efficiently prevent sequestration of 
parasitized erythrocytes in the microvasculature and, thus, 
impair disease progression. In contrast to the early belief that 
artemisinins modify the heme metabolic pathway we know 
now that the P. falciparum encoded sarcoplasmic–endoplasmic 
reticulum ATPase is most likely their true target.3
Clinically relevant and applicable artemisinins are rapidly 
metabolized in vivo to the biologically active dihydroarte-
misinin which has an elimination half-life of approximately 
45 minutes. Artemisinins also lack the quinine-associated 
property to induce life-threatening hypoglycemia.
In addition to its strong antimalarial effectiveness, 
A. annua has also been claimed to exhibit considerable 
anticancer properties. The active ingredients appear to be 
selectively toxic to distinct breast cancer cells4 and some 
forms of prostate cancer, and exciting results have been 
reported from experiments with leukemia cells5 and other 
cancer cells.6 Furthermore, A. annua is effective in killing 
young adult worms in infections with the several species 
of the trematode Schistosoma, which may cause human 
schistosomiasis.7 Standard therapy regimens of these 
conditions with artemisinin derivatives have, in contrast 
to human malaria management, not yet been established. 
Respective options are, however, under study.
Artemether
As artemether is now the most widely used artemisinin 
derivative in the treatment of malaria, we will refer in 
the following to that particular derivative if not indicated 
otherwise.
Artemether is fat-soluble and readily absorbed within 
2 hours after oral application. It is remarkably well tolerated, 
and peak serum levels occur within 1 hour of an oral dose 
and persist for up to 4 hours. The terminal phase elimination 
half-life is less than 1 hour. Co-administration with grapefruit 
juice and fat increases bioavailability.8 Artemether is 
demethylated by cytocrome P450 (CYP3A4)-mediated 
metabolic transformation.9 Dihydroartemisinin also exhibits 
antiparasite effects and is cleared rapidly, largely through 
the bile system.Therapeutics and Clinical Risk Management 2009:5 807
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The inherent advantage of artemether, but also of all other 
artemisinins, is its rapid effect on all asexual erythrocytic 
stages of the malaria parasite and on the sexual gametocytes. 
It prevents gametocyte development by its effect on 
trophozoites and on early (stage I–III) gametocytes.10 
In studies of more than 5000 malaria patients in Thailand 
it was convincingly demonstrated that gametocyte carriage 
occurred significantly less frequent among individuals who 
were treated with artemisinin derivatives than among those 
treated with mefloquine.11 Thus, apart from the extraordinary 
clinical benefit to the individual patient, efficient transmission 
of plasmodia is inhibited.12
The safety profile of artemether is remarkably good 
and the substance appears to be less toxic than quinine 
or chloroquine. Reports from clinical trials on serious 
adverse effects (SAEs) are scarce and include type 1 
hypersensitivity reactions in about 1 out of 3,000 patients as 
well as drug-induced fever, hypotension, tinnitus, transient 
and clinically insignificant reticulocytopenia, neutropenia, 
elevated SGOT and SGPT plasma levels, bradycardia and 
ECG abnormalities. In particular, a prolongation of the QT 
interval has been observed.13 Gastrointestinal disturbances 
such as nausea, abdominal pain, diarrhea after oral 
application, dark urine, sweats, jaundice and somnolence and 
dizziness, pain at the site of the injection, skin reactions, and 
fever may occur rarely. All adverse events are reversible.
In animals, intramuscular injection of artemether can cause 
neurotoxicity, in particular neuronal damage in brain stem 
nuclei,14,15 most likely due to sustained blood concentrations 
of artemether after injection of the oily drug. Neurotoxic 
effects in mice are less pronounced when artemether is given 
orally, although higher blood concentrations are achieved 
via the parenteral route.16 However, these findings were not 
confirmed to occur in humans.17 Artemisinins have shown 
toxic potential, but no teratogenic potential, in animal models 
and are thus contraindicated in the first trimester of pregnancy 
if alternatives are obtainable.18
Overdosage of artemether has not been reported to date. 
Experiments with large doses of artemether, however, suggest 
the occurrence of cardiac irregularities, eg, prolongation 
of the QTc interval and arrhythmias (mostly tachycardia), 
and disturbances of the central nervous system. An ECG 
should be documented prior to the initiation of treatment 
in all cardiac patients. Clinicians who are confronted with 
situations of artemisinin overdosage should examine gait 
and balance as well as alterations of the ocular motility 
and of peripheral reflexes. An antidote to artemether is not 
at hand.
As the half-life of artemether is extremely short, a safe 
cure cannot be relied on unless multidose treatment has 
been applied, eg, for 7 days with plasma levels above the 
minimal parasitocidal concentration. The use of artemisinins 
in monotherapy of malaria is, however, not recommended 
as it is associated with high incidences of recrudescent 
infection. In addition, combined treatment with a second drug 
is critically important in order to prevent the development of 
artemisinin resistance. The WHO has announced in 2006 that 
13 pharmaceutical companies have agreed to comply with the 
prudent recommendation to phase out single-drug artemisinin 
medicines for oral malaria treatment. Complying companies 
include the leading producers of high quality artemisinin-
based substances. They will now focus their marketing 
efforts primarily on combinatory drugs (artemisinin-based 
combination therapy, ACT).
Resistance to artemisinins
In experimental laboratory settings, the induction of persistent 
high-level resistance to artemisinins in P. falciparum is 
difficult to achieve. Rodent malarias, but also P. falciparum 
with a 5- to 10-fold reduced susceptibility, could be selected 
in vitro.19 P. falciparum multidrug resistance gene 1 (Pfmdr1) 
is associated with slight but significant reductions in 
susceptibility to artemisinins.20 In vitro data from French 
Guyana and Senegal indicate that inhibitory concentrations 
(IC) 50 values as high as 117 nmol/L and 45 nmol/L, 
respectively, were associated with mutations (S769N) in the 
SERCA-type PfATPase6.21 Data were collected in areas of 
unrestrained and unsupervised oral artemisinin application. 
Data that come from Cambodia and its border to neighboring 
Thailand are of concern as well. In this cradle area of drug 
resistance development and multidrug-resistant P. falciparum, 
treatment failure to artesunate-mefloquine as well as to 
AL already exceeds 10%,22 whereby it is unclear whether 
resistance to partner compounds of the artemisinins play a 
prominent role.23 Other investigators have found, in the very 
same area, a persistent high sensitivity of P. falciparum to 
artesunate–mefloquine, but steadily decreasing parasitological 
responses to artesunate, and an increase in gametocyte 
carriage of patients.24 Nevertheless, artemisinin derivatives 
have been used in this region for more than 30 years now and, 
most likely, exerted considerable cumulative evolutionary 
pressure on P. falciparum. Until now, in vitro resistance of 
parasite isolates appears to be inducible.20 A most recent 
alarming study from the Thai–Cambodian border raises, 
however, concern in this matter and clearly indicates 
the urgent need of appropriate containment measures.25 Therapeutics and Clinical Risk Management 2009:5 808
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The spread of artemisinin resistance westwards has also 
been addressed.26 Discrepancies between in vivo and in vitro 
data require careful exploration. Parasite isolates from most 
other parts of the world are still highly sensitive to arte-
misinins. We are, however, expecting now the first data sets 
from Kenya where corresponding studies on artemisinin 
resistance are being performed. In vitro, the median IC50 
for dihydroartemisinin and artesunate are usually below 
10 nmol/L. IC50s for artemether and artemisinin are typically 
2 to 3 times and 5 to 10 times higher, respectively.20
To delay the imminent emergence of resistance, 
artemisinins are now combined with longer-acting drugs, 
in particular with amodiaquine, mefloquine, sulfadoxine–
pyrimethamine or with lumefantrine. The addition of long-
acting drugs to artemisinins causes the elimination of residual 
parasites that were not readily disrupted by the fast-acting 
artemisinin. The combinatory drug that has been studied best 
so far is lumefantrine.
Lumefantrine
Lumefantrine (previously referred to as benflumetol) is 
a substance with distinct blood schizontocidal activities 
against a wide range of plasmodia, including P. falciparum 
and all other human plasmodia. Lumefantrine, a fluorene 
(benzindene)  derivative  (a-(dibutylaminomethyl)-
2,7-dichloro-9-(p-chlorobenzylidene)-5-fluorenemethanol), 
is an aryl-amino alcohol with intriguing similarities to 
other antimalarials (quinine, halofantrine, mefloquine). 
It has, however, and in contrast to these substances, never 
routinely been used as monotherapy in malaria. Lumefantrine 
originates, as does artemether, from malaria research in 
China. It was synthesized in the 1970s by the noncommercial 
Academy of Military Medical Sciences in Beijing27 and 
its effectiveness against all Plasmodium species that are 
pathogenic to humans has been documented and evaluated 
in several studies.9
Lumefantrine is highly lipophilic and resorption 
commences approximately two hours after administration. 
Peak plasma levels are found 6 to 8 hours after administration, 
whereby plasma levels may vary considerably between 
individuals.28 Concomitant consumption of food, in 
particular the intake of fat at a minimum amount of about 
1.2 g/dose of lumefantrine,29 enhances the bioavailability of 
both artemether and lumefantrine by the factors 2 and 16, 
respectively. Concerns that fat contents of meals in sub-Saharan 
Africa might not suffice for ample bioavailability of AL with 
convincing cure rates have been addressed in a recent review 
article and have been contradicted.30 However, an anecdotal 
case report indicates that insufficient fat intake or even 
starvation may result in treatment failure.31
The precise mode of the efficacy of lumefantrine on 
plasmodia is not fully understood. It results, most likely, 
from the interaction of heme, a degradation product of the 
hemoglobin metabolism, with the active ingredients in the 
digestive vacuole of the malaria parasite. It may, however, 
also interfere with the synthesis of nucleic acids and 
proteins. The activity of lumefantrine is slower than that 
of artemisinins and the recrudescence rate is low when the 
substance is given as recommended. Lumefantrine binds 
strongly to lipoproteins and has a terminal phase elimination 
half-life of approximately 86 hours.9 In dogs and rats, 
a direct glucuronidation takes place in vivo after oxidative 
biotransformation. In human liver microsomes, lumefantrine 
is N-dibutylated by CYP3A432 and, in vitro, lumefantrine 
inhibits at appropriate plasma concentrations significantly 
the activity of CYP2D6.
The pharmacokinetic properties of lumefantrine are 
reminiscent of characteristics of halofantrine, with variable 
oral bioavailability profiles, considerable augmentation of 
oral bioavailability through concomitant consumption of fat, 
and a terminal elimination half-life of 2 to 3 days in healthy 
volunteers and 4 to 6 days in patients with clinically relevant 
P. falciparum infections.33
Artemether–lumefantrine:  
the fixed-dose formulation
The rationale of using ACT is as follows: different half-lives 
of ACT compounds, with extremely short half-lives of 
Table 1 Countries by WHO region which have adopted artemether–lumefantrine (AL) as first-line drug policy for the treatment of 
uncomplicated falciparum malaria18
WHO region Country
Africa Angola, Benin, Botswanaa, Burkina Fasoa, Central African Republica, Chada,b, Comoros, Ethiopia, 
Gambia, Guinea-Bissaua, Kenya, Malawi, Malia, Mozambiquea, Namibia, Niger, Nigeria, Rwanda, 
South Africa, Togo, Uganda, United Republic of Tanzaniab, Zambia, Zimbabwea
Western Pacific Papua New Guineaa, Philippinesa,   vanuatua
aPolicy adopted but not fully implemented.   bAL adopted, but not exclusively; other ACTs in use as well.Therapeutics and Clinical Risk Management 2009:5 809
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artemisinin derivatives and long half-lives of the partner 
drugs cause a pharmacokinetic imbalance. The rapid onset 
of action of artemisinins reduces the biomass of the parasite 
within a short period of time. The remaining parasites are 
subject to elimination through the partner drug. This mode 
of action has proven highly effective. It implies, however, 
that the efficacy of ACTs critically depends on the parasite’s 
sensitivity to the non-artemisinin partner drug. In order 
to minimize the development of ACT resistance, fixed 
co-formulations are superior to two separate or co-blistered 
drugs, as fixed combinations explicitly exclude artemisinin 
monotherapy. Currently, 100 million ACT treatments are 
prescribed per year, approximately 75% of them with AL. 
AL is now registered in 79 countries. The second largest share 
of the market has artesunate–amodiaquine as a co-blistered 
formulation which is expected to be replaced in due time 
by a fixed-dose combination produced by Sanofi-Aventis.34 
Given that approximately 300 million malaria treatments 
are needed annually, the number of ACTs to be distributed 
could readily double by 2012. Taking into account the 
current absence of clinically significant resistance to these 
ACTs outside Cambodia and Thailand, they are likely to 
be the most commonly used ACTs for the next few years 
to come.
The combination of artemether with lumefantrine was 
developed in China and first evaluated in the 1960s. Based 
on the good results, Novartis was involved in the production 
and distribution of AL as Coartem® or Riamet®. It was 
the first fixed-dose antimalarial drug combination of an 
artemisinin derivative with an unrelated co-substance, in 
terms of biochemical and pharmacological properties. First, 
tablets containing 20/120 mg AL were introduced as a 4-dose 
regimen (total dose: 80/480 mg AL) to be administered 
at 0, 8, 24 and 48 hours of treatment. Pharmacokinetic–
pharmacodynamic (PK–PD) data, however, suggested that 
the main PK determinant of cure was either the area under the 
actual plasma lumefantrine concentration time curve (AUC) 
or, as a proxy, the concentration of lumefantrine at day 7.27 
Lumefantrine plasma concentrations at day 7 of 500 ng/mL 
are required to result in cure rares of more than 90%, but 
such success could not be reproducibly and reliably achieved 
with the 4-dose regimen. To increase the AUC, a 6-dose 
regimen was then tested and proved highly effective and 
well tolerated in adults when each 4 tablets were given at 
0, 8, 24, 36, 48 and 60 hours of the treatment course.35 When 
comparing the 6-dose regimen over 60 hours with the 6-dose 
regimen over 96 hours with tablets given at 0, 8, 24, 48, 72 
and 96 hours, the 28-day cure rates were still slightly higher.35 
In children, appropriately bodyweight-adjusted AL doses 
are recommended. Children with weights of 5/15 kg, 
15/25 kg and 25/35 kg should receive 1, 2 and 
3 tablets, respectively, per time point. Demographic variables 
such as gender, body weight, age and ethnicity do not appear 
to affect the pharmacokinetics of AL. If vomiting occurs 
within one hour of administration, an equal dose of AL 
should be given again.
Artemether–lumefantrine:  
drug interactions
Administration of AL together with ketoconazole, a potent 
CYP3A4 inhibitor, resulted in elevated plasma levels of 
artemether, dihydroartemisinin and lumefantrine. These 
increases were, however, considered clinically insignificant,32 
as were decreases in the lumefantrine AUC when mefloquine, 
a CYP3A4 substrate as well, was simultaneously given to 
healthy individuals.36 As antiretroviral drugs are powerful 
modulators of CYP enzymes, validated pharmacokinetic 
data on their interactions with AL are now urgently needed. 
Patients who are undergoing antiretroviral treatment should 
be examined regularly during a treatment course with AL.
When switching from AL to quinine during a treatment 
course, the long elimination half-life of lumefantrin must 
be considered and careful ECG monitoring is essential. 
Pretreatment with mefloquine does not modify the plasma 
concentration of artemether or the ratio artemether–
dihydroartemisinin. However, a significant decline of 
plasma lumefantrine levels may occur, most likely due to a 
mefloquine-induced decreased resorption that is induced by 
diminished production and output of bile.
Artemether–lumefantrine: 
side effects, cautions and 
contraindications
AL is tolerated very well in the majority of cases. A tolerability 
superior to that of mefloquine alone or to the combination of 
mefloquine with artesunate has repeatedly been observed.37,38 
Adverse effects that were reported include gastrointestinal 
irritations, headache, dizziness, fatigue, sleep disturbances, 
rash, palpitations, myalgia and arthralgia.39 Evidence of 
cardiotoxicity, which may be expected due to structural 
similarities of lumefantrine with mefloquine, quinine, and 
halofantrine, is weak. In fact, in healthy volunteers as well as 
in patients, clinical studies could not demonstrate significant 
changes in the QTc interval, or a correlation between plasma 
lumefantrine levels and QTc intervals.40,41 One study has Therapeutics and Clinical Risk Management 2009:5 810
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indicated a modestly increased risk of QTc prolongation 
when AL was given to healthy individuals together with 
quinine intravenously.32 Data on cardiotoxicity of artemisinin 
derivatives in general, and of artemether in particular, have 
shown clinically insignificant ECG abnormalities in 1.3% 
of more than 2600 patients who were suveyed.13 However, 
as in several studies asymptomatic prolongations of the QTc 
intervals have been described, the manufacturing company 
has decided to restrain from recommending AL for patients 
with recognized cardiac arrhythmias and for patients who 
are on medications potentially affecting the QTc interval. 
Studies of patients with renal or hepatic impairment have 
not been conducted so far.
Initial reports on irreversible audiometric changes in 
humans treated with AL have raised concern.42 Further 
careful evaluation in a randomized trial, however, has not 
confirmed any detrimental effects of standard oral regimens 
of AL on peripheral hearing or brainstem auditory pathways 
in patients with falciparum malaria.43
According to the manufacturer, approximately 20 distinct 
SAEs were observed in more than 1800 patients treated. 
These include severe anemia in children, pneumonia, 
hepatitis, and one case of hemolytic anemia and others, all of 
which could even have been caused by the malaria infection 
itself.13 Because of the unavailability of validated data, AL 
should not be given to pregnant or breast-feeding women 
and clinicians should use AL in these patients only when 
alternatives are either not obtainable or contraindicated.18 
This applies also to children with body weights less than 5 kg. 
Overall, the tolerability and safety profile of AL is favorable, 
while drug interactions should be subject to clinical notice 
and trigger further research.
Procurement of artemether–
lumefantrine by WHO
AL has been included in the WHO Model List of Essential 
Medicines for adults and children (http://www.who.int/
medicines/publications/essentialmedicines/en/), a list of 
essential medicines compiled by a group of independent 
experts who select basically essential drugs according to their 
public health relevance, evidence of efficacy and safety, and 
competitive cost-effectiveness. Novartis, the manufacturer of 
AL, and WHO have formally agreed to collaborate in order 
to increase the access to AL in developing countries. Through 
this collaboration, WHO intends to achieve a broad and 
equitable availability of safe and effective malaria treatment 
and, in addition, contribute to the control of drug resistance. 
In its function as a technical adviser to member states, WHO 
wants to contribute to both national drug policy changes and 
rational drug use.
Despite strong efforts to modify the properties and galenics 
of AL, it still has a limited shelf-life of 24 months only. This 
requires efficient distribution infrastructures on all levels of 
health care systems. The problem applies in particular to those 
developing countries which have adopted AL as first-line 
drug for the treatment of uncomplicated falciparum malaria. 
These countries face the challenge of supplying AL to remote 
primary health care facilities and to assure correct storage of 
sufficient amounts of the medicines.
Most recent data indicate that AL tablets may be 
chemically and physically stable well beyond the stated shelf-
life even under tropical, ie, warm, conditions.44 These data 
should, however, not pave the way for a permissive attitude 
about the stability of AL tablets, but rather lead to thorough 
investigation and examinations and, if possible, chemical and 
galenic improvement.
UNICEF and other official agencies as well as non-
governmental organizations have established direct procurement 
agreements with Novartis to supply AL at the cost that was 
negotiated by WHO. As a direct consequence, a smaller 
proportion of AL was procured through WHO in 2007.1
Soluble formulations of artemether–
lumefantrine for children
A 3-day, 6-dose regimen of AL is efficacious and safe both 
in adults and children.45,46 Infants and children can safely be 
treated when weighing 5 kg or more. AL was found to have 
an efficacy of 90% or more in African children at day 28 of 
treatment. This was even true under unsupervised outpatient 
conditions when nutritional advice, namely intake with fatty 
food, was given.47 Young children are, especially if they 
are sick, not able to swallow the AL tablets. In everyday 
practice, crushing of the tablets and administering them with 
water is the typical solution of this problem. This, however, 
results in a bitter tasting solution, potentially compromising 
tolerability and compliance. To overcome these problems, 
dispersible tablets (Coartem® Dispersible) have been tailored 
for exclusive pediatric use by Novartis in collaboration with 
Medicines for Malaria Venture (MMV). The main features of 
Coartem® were maintained as far as possible, in particular the 
strength of the dosage (20 mg A/120 mg L) per dispersible 
tablet. The sweetened and cherry-flavored dispersible tablets 
have to be added to a small amount of water and administered 
without delay orally once disintegrated to a suspension. 
Rinsing the water glass is recommended to ensure complete 
administration.Therapeutics and Clinical Risk Management 2009:5 811
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Table 2 Therapeutic effects of artemether–lumefantrine (6-dose regimen; standard tablets of 20/120 mg AL) in children in malaria-endemic 
areas with uncomplicated falciparum malaria – comparison to other antimalarial compounds
Drugs tested vs AL Country n Main conclusion Scorea Reference
AS-SMP-PYR Cameroon, Mali, 
Rwanda, Sudan
1,384 Similar effectiveness, efficacy 
and tolerability
+/− 52
AQ-AS Ghana 246 Equal clinical and parasitological 
responses; more late clinical 
failures with AL;   AL less well 
accepted
− 53
CQ-SUL-PYR  
AS-SUL-PYR 
DHA-PiP
Papua New Guinea 482 AL most effective + 54
DHA-PiP Kenya 146 Faster parasite clearance  
with AL
+ 55
AS-MQ Mali 470 Similar cure rates; more new 
infections after treatment  
with AL
− 56
AS-AQ Ghana 227 Both equally effective and well 
tolerated
+/− 57
AS-AQ  
AS-CPG-DAP
Ghana 534 Similar effectiveness and 
tolerability
+/− 58
DHA-PiP Uganda 414 Similar efficacy; higher risk of 
reinfection in AL group, higher 
risk of gametocytemia in AL 
group; equally well tolerated
− 59
AS-AQ Nigeria 132 Equal efficacy and safety +/− 60
AS-AQ Tanzania 157 Similar efficacy after PCR 
adjustment
61
AQ-SUL-PYR  
DHA-PiP
Burkina Faso 559 Similar risk of genotype-
adjusted treatment failure, 
equally well tolerated
+/− 62
SUL-PYR Nepal 99 AL more effective than 
comparison drug
+ 63
AQ-SFL-PYR Nigeria 181 Similar efficacy, tolerability, and 
gametocyte-carrier rate; faster 
parasite clearance in the AL 
group
+ 64
AS-SUL-PYR Sudan 160 Both regimens highly effective +/− 65
AS-AQ  
AS-MQ  
AQ-SUL-PYR
Senegal 955 All combinations after PCR 
correction similarly effective 
and well tolerated
+/− 66
DHA-PiP Uganda 421 Higher risk of recurrent 
parasitemia and gametocytemia 
in the AL group
− 67
AQ-SUL-PYR  
AQ-AS
Uganda 601 AL was the most efficacious 
treatment
+ 68
DHA-PiP indonesia 774 Both equally safe and effective 
after PCR correction; higher 
risk of reinfection in the AL 
group
− 69
AQ-SUL-PYR Burkina Faso 521 AL less effective − 70
AQ-SUL-PYR Rwanda 500 AL more efficacious than 
comparison drug
+ 71
MQ-AS Cambodia 190 Lower cure rates in AL, 
possibly due to low levels 
of lumefantrine in blood or 
lumefantrine resistance
− 23
(Continued)Therapeutics and Clinical Risk Management 2009:5 812
Ehrhardt and Meyer Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Table 2 (Continued)
Drugs tested vs AL Country n Main conclusion Scorea Reference
AS-SUL-PYR  
AS-AQ
Republic of Congo 298 Better efficacy and fewer reinfections in 
the AL group
+ 72
AS-SMP-PYR Mali 606 Same efficacy/safety profile as AL; both 
well tolerated
+/− 73
AS-AQ Uganda 408 Equal efficacy;   AL superior in preventing 
new infections
+ 74
AS-AQ Angola 137 Equal efficacy +/− 75
AS-AQ Nigeria 119 Equally high efficacy and tolerability +/− 76
AS-SUL-PYR Sudan 143 Equally high efficacy and tolerability +/− 77
AS-MQ Thailand 490 Equally high efficacy +/− 78
AS-AQ Tanzania (Zanzibar) 408 Equal efficacy;   AL superior in preventing 
new infections
+ 79
CQ-SUL-PYR  
AS-MQ
Bangladesh 364 Both ACTs effective, well tolerated, 
reduced gametocyte carriage
+/− 80
CQ  
SUL-PYR AS-AQ
Ghana 168 Rapid fever, parasite and gametocyte 
clearance in the studied ACTs
+/− 81
CQ-SUL-PYR The Gambia 497 AL reduced risk of gametocyte-carriage 
and gametocyte density post-treatment
+ 82
AQ AQ-SUL-PYR  
AS-AQ
Tanzania 1811 Best effectiveness and least recrudes-
cences in the AL group
+ 83
AS-MQ Lao People’s Democratic 
Republic
108 Equally high efficacy and tolerability +/− 84
CQ-SUL-PYR  
AS-MQ
Lao People’s Democratic 
Republic
330 Both ACTs highly effective +/− 85
AS-MQ Thailand 219 Similar efficacy and tolerability +/− 86
AS-MQ Thailand 200 AL equally effective but better tolerated + 87
Notes: Randomized, comparative efficacy and/or efficiency trials found in PubMed when search terms “artemether AND lumefantrine” were entered are included in the table. 
Only trials that were published in English are considered.
aScoring refers to the comparisons of AL with other components; +, −, +/−,   AL superior, inferior, equal, respectively, to the comparison drugs; bchildren and adults.
Abbreviations: AL, artemether–lumefantrine; ACT, artemisinin combination therapy; n, number of randomized study participants; AS, artesunate; CPG, chlorproguanil; 
CQ, chloroquine; DAP, dapsone; DHA, dihydroartemisinin; MQ, mefloquin; PIP, piperaquine; PYR, parimethamine; SFL, sulfalene; SMP, sulphamethoxypyrazine; SUL, sulfadoxine.
In  a  randomized,  multicenter,  non-inferiority, 
investigator-masked clinical trial including 899 children in 
Benin, Mali, Kenya, Tanzania/Zanzibar and Mozambique, 
the 28-day parasitological cure rate (PCR corrected) in the 
per-protocol analysis was 97.8% (95% confidence interval 
[CI], 96.3 to 99.2) for dispersible tablets and 98.5% (95% 
CI, 97.4 to 99.7) for the administration of crushed tablets.48 
In the intention-to-treat analysis of this study, these figures 
were 95% and 96.2%, respectively. The safety profile of 
dispersible AL tablets also equals that of the standard tablets. 
The costs of this formulation are identical to those of the 
standard formulation. Several African countries have already 
approved the dispersible galenics of AL. Novartis has now 
applied for the inclusion of Coartem® Dispersible in the WHO 
Model List of Essential Medicines for Children, a step that 
appears reasonable and justified.
Another soluble formulation, a dry powder containing 
15 mg Artemether and 90 mg Lumefantrine per 5 mL of 
liquid after reconstitution (Co-Artesiane®; Dafra Pharma), 
was successfully tested against AL standard tablets in a 
randomized, controlled, open-label trial in Kenya.49 The results 
of this study did also not indicate any differences in cure rates 
or safety, though they had a lower statistical power to do so.
Trials on the efficacy of artemether-
lumefantrine in children
Table 2 lists clinical trials from Africa and Asia in which the 
therapeutic effects and/or the tolerability and/or the risk of 
reinfections of the 6-dose AL regimen with standard tablets 
in children in malaria-endemic areas with uncomplicated 
falciparum malaria were compared to that of other 
antimalarials. The studies listed in Table 2 are based on a 
NCBI-PubMed review with the search terms “artemether 
AND lumefantrine” and did not adhere to the stringent 
selection criteria which are applied for the meta-analyses 
of the Cochrane Infectious Diseases Group Specialized Therapeutics and Clinical Risk Management 2009:5 813
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Register. Notably, in several studies only small numbers of 
participants were enrolled.
Although the conclusions that came from the various 
comparative studies are partly inconsistent and, in some 
cases, dependent on inherent differences in reporting, they 
clearly demonstrate the favorable tolerability, high efficacy 
and adequate parasitological responses to ACT in general and 
in particular to the standard 6-dose regimen. In the majority 
of the comparisons, the overall evaluation of AL appears 
superior to the comparison substances. In those studies 
where AL was rated inferior to the comparison drug or drug 
combination it is worth to note that in all studies, except 
one, artemisinin derivatives were part of the comparison. 
The overall good effectiveness and tolerability is in line with 
the 2005 Cochrane Database Systematic Review,50 which 
concludes that, after evaluation of 9 clinical trials, the 6-dose 
regimen of AL appears to be more effective than antimalarial 
regimens not containing artemisinin derivatives.
Conclusion
Although resistance now appears to be emerging, ACT 
treatment is still the best choice that we have at present 
for the treatment of uncomplicated P. falciparum malaria, 
both in disease of children and adults. It is sufficiently well 
tolerated and effective and some degree of resistance against 
the constituent components has only recently been reported. 
This situation certainly requires attentive monitoring and 
the development of containment strategies. The dispersible 
formulation of AL for use in pediatric malaria is an important 
and favorable improvement, as it will certainly enhance the 
compliance of affected children and of the parents who care 
for them. However, we are desperately waiting for the effective 
(at best 99% or so) malaria vaccine, which is not in sight yet. 
Recent encouraging observations on the RTS,S/AS01E vaccine 
that is still undergoing evaluation in several regions show an 
adjusted efficacy rate of 53%.51 Until comprehensive coverage 
with an effective vaccine we have to cope with and explore and 
improve all available and attainable preventive and therapeutic 
options in order to reduce the intolerable burden of malaria.
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